#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC.81% HER2-positive Promising antitumor activity Higher HER

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-24 17:06· 2 天前评分70

正文 · 原文

#ESMO26 | WUTSUP-02 (Phase II, n=42) Neoadjuvant disitamab vedotin + perioperative tislelizumab in high-risk, non-met UTUC.81% HER2-positive Promising antitumor activity Higher HER2 expression may predict response. @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily

33 浏览 · 1 赞 · 1 转发 · 0 回复

来源：Martin ZapataLaguado · x.com